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Background: Exacerbation is one of the most significant problems in patients with
asthma. Although subpopulation of patients is more susceptible to exacerbations
than others, which clinical features characterise susceptibility to exacerbation are
not well understood.
Methods: Consecutive non-smoking adult patients with asthma who had multiple
exacerbations (ME) despite regular maintenance treatment were compared with
those who had at most single exacerbation as control during the previous 1 year.
Exacerbation of asthma is defined initiations or escalations of systemic corticoster-
oid as part of the management for aggravated asthma condition.
Results: Patients with ME (n ¼ 32, male: 6, mean age: 46.7 years) were
characterised by intensive current maintenance treatment (dose of inhaled
corticosteroid; 1037.57452.8 vs 621.67257.3 mg, P ¼ 0:0005, proportion of oral
corticosteroid users; 28.1% vs 2.7%, P ¼ 0:008), severe episodes of exacerbation
(asthma-related hospitalisations; 71.9% vs 23.4%, P ¼ 0:0002, arrival on ambulance;
37.5% vs 8.1%, P ¼ 0:008), concomitant chronic sinusitis (34.4% vs 10.8%, P ¼ 0:038)
and intolerance to non-steroidal anti-inflammatory drugs (NSAIDs) (34.4% vs 5.4%,
P ¼ 0:006) in comparison with controls (n ¼ 37, male:11, mean age:44.4).
Pulmonary function in patients with ME was characterised by persistent airflow
limitation and reduced reversibility.
Conclusion: Patients with ME are at increased risk for severe exacerbation despite
more intensive maintenance anti-inflammatory treatment. Persistent irreversible
airflow limitation and complications of chronic sinusitis and/or NSAIDs intolerance
are characteristics to this subpopulation.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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With the advent of potent anti-inflammatory med-
ications such as inhaled corticosteroid (ICS) and
practical guidelines for their appropriate applica-
tions, majority of patients with asthma benefit by
attaining favourable control over the disease.1
However, it is becoming increasingly clear that
subpopulation of asthmatics are still having com-
promised quality of life due to frequent exacerba-
tions2,3 regardless of currently available treatment.4
They are at greater risk to develop severe exacer-
bations that convey time off work, admission to
hospitals, and more importantly, life-threatening
episodes.5 Frequent medical resource utilisation
produces disproportionately high health care ex-
penditure by this population relative to remaining
patients with controlled disease,3 who account for
majority of whole patients of asthma. Furthermore,
there remains much room for improvement in the
treatment and prevention of acute attacks2 in terms
of efficacy. Despite these critical situations, little is
known about underlying pathophysiology of these
patients who remain susceptible to exacerbations.
Since currently available treatment options are
limited and not promising,6 these patients should
be identified and managed with special attention to
minimise socioeconomic burden and severe, espe-
cially lethal attacks. In this context, it is urgent to
characterise patients who have frequent exacerba-
tions not only for identifying affected individuals to
deliver optimised management but also for gaining
insight into the underlying pathophysiology of the
condition. Thus, we conducted the present investi-
gation to characterise patients with asthma who had
multiple exacerbations (ME) in a year despite
maintenance treatment by comparing patients with
stable asthma.Methods
Subjects
Non-smoking adult patients with asthma were
consecutively recruited during April 2002 to March
2003 at Kurume University Hospital with informed
consent to the investigation. All subjects were
regular attendants to outpatient clinic of the
hospital for at least previous two consecutive years
where care was given by asthma specialist based on
a practice guideline (global initiative for asthma
(GINA)).5 The diagnosis of asthma was established
by reversible airflow obstruction that occurs natu-
rally or after treatment, and/or airway hyperre-sponsiveness.5 Patients who have coexisting
conditions that may compromise lung functions,
such as dust exposure, bronchiectasis or parench-
ymal lung diseases were not included in the study.
Patients who were considered by the physicians to
comply poorly with treatment were excluded. All
subjects were recruited when their asthma condi-
tion was stable without change in medications for
at least 2 months and free of sings of respiratory
infections. Asthma exacerbations were defined as
initiations of or escalations of systemic corticoster-
oid required for aggravated asthma condition
judged by the physicians.7 Patients who had
exacerbations more than twice during the previous
1 year of the recruitment were compared with
those with at most one exacerbation. The study
protocol was reviewed and approved by the ethical
committee of Kurume University Hospital.Questionnaire
A structured questionnaire was used to obtain
information on asthma-related histories (age of
onset, family history of asthma, hospital admission
and emergency visit on ambulance ever due to
asthma), current medications, and concomitant
allergic conditions (allergic rhinitis, chronic sinusi-
tis/nasal polyps, and histories of intolerance to
non-steroidal anti-inflammatory drugs (NSAIDs)).
The age of asthma onset was based on patient’s
own report, or if not available, was inferred from
the clinical history suggestive of asthma. Childhood
asthma was defined by asthma started before 10
years of age.Pulmonary function test and laboratory tests
Pulmonary function test (PFT) was performed as
directed previously.8 All measurements were made
in the sitting position between 8:30 and 10:30 in
the morning. Baseline measurement was evaluated
after discontinuation of all forms of b2 adrenergic
agonist for 12 h. Forced expiratory volume in 1 s
(FEV1) and forced vital capacity (FVC) were
obtained using a dry spirometer (Chestak-33, Chest
MI Inc. Tokyo, Japan) before and 30min after
administration of 400 mg of salbutamol by pres-
surised metered-dose inhaler. The largest values
from the first three technically satisfactory forced
expirations were selected in each occasion. BDR
was expressed as the absolute change volume in
FEV1 (dFEV1) and its normalised value to predicted
FEV1 (%dFEV1).
9,10 Complete blood count and serum
IgE were determined at the same time as the
performance of PFT.
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Comparisons were performed using w2 test or
Mann–Whitney U-test where appropriate. A P value
less than 0.05 was considered significant. The
program used for the analyses was JMP software
(SAS Institute Inc. Cary, NC, USA).Results
Table 1 summarises characteristics of the subjects.
There were no significant differences in age
(46.7718.4 vs 44.4715.7 years, P ¼ 0:55), gender
(proportion of male: 27.3 vs 34.4%, P ¼ 0:44). There
was a significant difference in the maintenance
treatment of the subjects; the dose of ICS was
significantly higher (1090.97464.9 vs 630.07
258.4mg, P ¼ 0:0005) and the proportion of regular
user of oral corticosteroid user was significantly
higher (7 (31.8%) vs 1 (0.4%), P ¼ 0:016) in patients
with ME than in control patients. Duration of asthma
was significantly longer in patients with ME than in
control patients (29.1718.0 vs 11.0713.1 years,
P ¼ 0:008). There were no significant differences in
family history of asthma (53.1 vs 32.4%, P ¼ 0:32)
and childhood asthma (25.0 vs 18.9%, P ¼ 0:75).
Asthma-related hospital admission was significantly
more frequent (71.9 vs 24.3%, P ¼ 0:0002) in
patients with ME than in control patients. Likewise,
12 out of 32 patients (37.5%) have ever utilised
ambulance for emergency visit in patients with ME,
whereas three out of 37 (8.1%) have in control
patients (P ¼ 0:008).
Among concomitant allergic conditions, the pre-
valence allergic rhinitis was not different (50.0 vsTable 1 Comparison of patient characteristics.
ME
n 32
Age 46.7718.4
Male (%) 6 (27.3)
Duration of asthma (years) 29.1718.0
Family history of asthma (%) 17 (53.1)
Childhood asthma (%) 8 (25.0)
Admissions (%) 23 (71.9)
Visit on ambulance (%) 12(37.5)
ICS (mg/day) 1037.57452.
Oral steroid (%) 9 (28.1)
Nasal allergy (%) 16 (50.0)
Chronic sinusitis (%) 11 (34.4)
NSAIDs intolerance (%) 11 (34.4)64.9%, P ¼ 0:31), whereas that of chronic sinusitis
was significantly higher in patients with ME (34.4%)
compared with control patients (10.8%, P ¼ 0:038).
The prevalence of allergic reactions to NSAIDs was
significantly higher in patients with ME (34.4%) than
in control patients (5.4%, P ¼ 0:006).
Table 2 presents the results of PFT. Although
there was no significant difference in %FEV1
(75.8723.9 vs 84.9718.9%, P ¼ 0:17), there was
a significant difference in FEV1/FVC (63.8715.0 vs
74.6711.2%, P ¼ 0:004) between patients with ME
and control patients. %FEV1 after administration of
bronchodilator tends to be lower in patients with
ME than in control patients (82.4724.0 vs
95.0717.5%, P ¼ 0:051). As was baseline value,
there was a significant difference in FEV1/FVC,
being lower in patients with ME than in control
patients (66.0716.8 vs 78.5711.6%, P ¼ 0:002).
Reversibility of FEV1 in response to the administra-
tion of bronchodilator was significantly reduced in
patients with ME than in control patients.
(148.87125.5 vs 275.17216.0ml, P ¼ 0:007) Nor-
malisation of the reversibility to predicted value of
FEV1 presented the same tendency (6.676.3 vs
10.277.6%, P ¼ 0:018).
Comparison of peripheral blood counts and serum
IgE were presented in Table 3. Patients with ME had
significantly increased numbers of WBC (6777.57
1644.3 vs 5777.071479.5/ml, P ¼ 0:024) and neu-
trophils (3832.371534.0 vs 3131.171049.3/ml,
P ¼ 0:016) compared with control patients. Num-
ber of eosinophils did not differ significantly
(432.87321.7 vs 373.67428.2/ml, P ¼ 0:13). There
was no significant difference in serum IgE between
patients with ME (432.87321.7 U/ml) and control
patients (373.67428.2U/ml, P ¼ 0:13).Control P
37
44.4715.7 0.55
11 (34.4) 0.44
11.0713.1 0.008
12 (32.4) 0.13
7 (18.9) 0.75
9 (24.3) 0.0002
3 (8.1) 0.008
8 621.67257.3 0.0005
1 (2.7) 0.008
24 (64.9) 0.31
4(10.8) 0.038
2 (5.4) 0.006
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Table 2 Comparison of pulmonary functions.
ME Control P
%FEV1 (%) 75.8723.9 84.9718.9 0.17
FEV1/FVC (%) 63.8715.9 74.6711.2 0.004
%FEV1 (post) (%) 82.4724.0 95.0717.5 0.051
FEV1/FVC (post) (%) 66.0716.8 78.5711.6 0.002
dFEV1 (ml) 148.87125.5 275.17216.0 0.007
%dFEV1 (%) 6.676.3 10.277.6 0.018
Table 3 Comparison of peripheral blood count and serum IgE.
ME Control P
WBC (/ml) 6775.07644.3 5777.871479.5 0.024
Neutrophil (%) 55.6713.3 53.978.5 0.22
Neutrophil (/ml) 3832.371534.0 3131.171049.3 0.016
Eosinophil (%) 6.673.8 7.075.4 0.9
Eosinophil (/ml) 411.07275.5 404.07337.0 0.56
IgE (U/ml) 432.87321.7 373.67428.2 0.13
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The present study clarified several characters of
patients with ME in comparison with control
patients with stable asthma. Current maintenance
medications demonstrates that patients with ME
require significantly more intense treatment to
maintain control compared with patients with
stable asthma, indicating that they have more
severe disease.11 It is possible that current medica-
tions are not enough in efficacy to suppress airways
inflammation in this population, rendering them
more susceptible to exacerbation. Sont et al.12
have demonstrated that management of asthma
utilising airway hyperresponsiveness as a supple-
mental objective parameter to apply medications
achieved better control over conventional manage-
ment based on a practical guideline, suggesting
that maintenance treatment was insufficient in
some of the patients with ME in the present study.
Furthermore, airways inflammation does not seem
to respond corticosteroid in a subpopulation of
patients with asthma.13 Therefore, the efficacy of
anti-inflammatory treatment is ideally required to
be monitored by objective means such as airway
hyperresponsiveness and/or induced sputum14 in
addition to subjective symptoms and spirometer or
peak flow meter, common measures to evaluate
asthma control in practice,5 in patients who
experience frequent or severe exacerbation toensure that airways inflammation is actually alle-
viated. Medical histories indicated that patients
with ME had more severe exacerbations, which was
reflected in the higher rates of asthma-related
hospitalisation and emergency visit on ambulance,
suggesting that patients with ME have predilection
not only to more frequent but also to more intense
exacerbations. Thus, these patients should be
managed with any possible measures and interven-
tions to prevent exacerbations, which may even-
tually reduce the risk of fatal events.15 The present
study also demonstrated that patients with ME
complicate chronic sinusitis and NSAIDs intolerance
significantly more frequently than do control
patients with asthma. Although the diagnosis of
these conditions are not confirmed by standardised
methods such as sinus CT for sinusitis and oral
challenge test for NSAIDs intolerance in this
investigation, they are known to have a close
association with severe form of asthma.16 These
results suggest that some of these patients have
aspirin-induced or aspirin-intolerant asthma, which
is relatively frequent in Japan.6
PFT results of the study appear to be relevant to
the underlying pathophysiology of the increased
susceptibility. The results showed that patients
with ME have significantly reduced FEV1/FVC and
reversibility of airflow obstruction in response to
short-acting b2 agonist than do control patients.
Since FEV1/FVC is a more sensitive parameter to
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characterise pulmonary function impairment in
patients with ME as a persistent airflow limitation.
Although not assessed in the present study, airway
responsiveness is shown to correlate negatively with
reversibility in airflow limitation,18 suggesting that
patients with ME have increased airway responsive-
ness. Taken together, persistently narrowed airways
that have hypersensitiveness to various broncho-
constricting stimuli can be one of the critical
pathologies of patients with ME. A morphometric
analysis of airways utilising high-resolution com-
puted tomography revealed that persistent irrever-
sible airflow limitation is associated with airway wall
thickening in patients with asthma.19 It is becoming
increasingly clear that several pathological elements
contribute to the development of airway wall
thickening, including airway wall infiltration of
inflammatory cells, thickening of basement mem-
brane, increased airway smooth muscle mass, and
edema, which are collectively apprehended as
airway remodelling (reviewed in Davies et al.20).
Airway remodelling has been documented to have an
intimate association with airway responsiveness.21
Considering the fact that exaggerated airway
hyperresponsiveness is a predictor of asthma ex-
acerbation,22 it can be speculated that susceptibility
to exacerbation may be mediated, at least in part,
by developed airway remodelling in subgroup of
patients with asthma. In this context, it is note-
worthy that similarity in pathology between remo-
delled airways in asthma and upper airways in
chronic sinusitis,23 which has been linked with ME in
this investigation, may suggest an intimate associa-
tion between the two conditions.
Peripheral blood count revealed that patients
with ME have significantly increased numbers of
WBC and neutrophils than do control patients. In
contrast there was no significant difference in the
number of peripheral blood eosinophils.
These results are in concert with the character of
severe asthma identified by a multicenter study for
severe asthma.24 Underlying mechanism of the
increased number of neutrophils are not known;
however, it can be speculated that higher dose of
corticosteroid contributes by way of inhibiting
apoptosis of neutrophils.25
The present study is notable in that frequent
exacerbations have intimate associations with
several clinical characters, which may in turn
enable clinicians to identify patients at risk and
deliver optimised management, although a limited
number of subjects were analysed. Clarification of
underlying pathophysiology of these characters
may give clues to better understanding of asthma
presenting frequent exacerbations.References
1. Schatz M, Cook EF, Nakahiro R, Petitti D. Inhaled corticos-
teroids and allergy specialty care reduce emergency
hospital use for asthma. J Allergy Clin Immunol 2003;
111(3):503–8.
2. American Thoracic Society. Proceedings of the ATS workshop
on refractory asthma: current understanding, recommenda-
tions, and unanswered questions. Am J Respir Crit Care Med
2000; 162(6): 2341–51.
3. Van Ganse E, Laforest L, Pietri G, et al. Persistent asthma:
disease control, resource utilisation and direct costs. Eur
Respir J 2002;20(2):260–7.
4. Walsh LJ, Wong CA, Cooper S, Guhan AR, Pringle M,
Tattersfield AE. Morbidity from asthma in relation to regular
treatment: a community based study. Thorax 1999;
54(4):296–300.
5. Asthma GIf (National Heart, Lung and Blood Institute).
Global strategy for asthma management and prevention.
2002.
6. Barnes PJ, Woolcock AJ. Difficult asthma. Eur Respir
J 1998;12(5):1209–18.
7. Oshita Y, Koga T, Kamimura T, Matsuo K, Rikimaru T, Aizawa
H. Increased circulating 92 kDa matrix metalloproteinase
(MMP-9) activity in exacerbations of asthma. Thorax
2003;58(9):757–60.
8. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R,
Yernault JC. Lung volumes and forced ventilatory flows.
Report Working Party Standardisation of Lung Function
Tests, European Community for Steel and Coal. Official
Statement of the European Respiratory Society. Eur Respir
J Suppl 1993;16:5–40.
9. Chhabra SK, Vijayan VK, Gupta R, De S. Expression of
bronchodilator response: comparison of four indices. Respir
Med 2002;96(8):611–4.
10. Quadrelli SA, Roncoroni AJ, Montiel GC. Evaluation of
bronchodilator response in patients with airway obstruction.
Respir Med 1999;93(9):630–6.
11. Cockcroft DW, Swystun VA. Asthma control versus asthma
severity. J Allergy Clin Immunol 1996;98:1016–8.
12. Sont JK, Willems LNA, Bel EH. Clinical control and
histopathologic outcome of asthma when using
airway hyperresponsiveness as an additional guide to long-
term treatment. Am J Respir Crit Care Med 1999;
159:1043–51.
13. Louis R, Lau LC, Bron AO, Roldaan AC, Radermecker M,
Djukanovic R. The relationship between airways inflamma-
tion and asthma severity. Am J Respir Crit Care Med
2000;161(1):9–16.
14. ten Brinke A, Zwinderman A, Sterk P, Rabe K, Bel E. Factors
associated with persistent airflow Limitation in
severe asthma. Am J Respir Crit Care Med 2001;
164(5):744–8.
15. Molfino NA, Nannini LJ, Rebuck AS, Slutsky AS. The fatality-
prone asthmatic patient. Follow-up study after near-fatal
attacks. Chest 1992;101(3):621–3.
16. ten Brinke A, Grootendorst DC, Schmidt JT, et al. Chronic
sinusitis in severe asthma is related to sputum eosinophilia.
J Allergy Clin Immunol 2002;109(4):621–6.
17. Enright PL, Lebowitz MD, Cockroft DW. Physiologic mea-
sures: pulmonary function tests. Asthma outcome. Am J
Respir Crit Care Med 1994;149(2 Pt 2):S9–S18 [discussion
S19–20].
18. Rasmussen F, Taylor DR, Flannery EM, et al. Risk factors for
airway remodeling in asthma manifested by a low post-
bronchodilator FEV1/vital capacity ratio: a longitudinal
ARTICLE IN PRESS
T. Koga et al.278population study from childhood to adulthood. Am J Respir
Crit Care Med 2002;165(11):1480–8.
19. Kasahara K, Shiba K, Ozawa T, Okuda K, Adachi M.
Correlation between the bronchial subepithelial layer and
whole airway wall thickness in patients with asthma. Thorax
2002;57(3):242–6.
20. Davies DE, Wicks J, Powell RM, Puddicombe S, Holgate ST.
Airway remodeling in asthma: new insights. J Allergy Clin
Immunol 2003;111:215–25.
21. Chetta A, Foresi A, Del Donno M, Bertorelli G, Pesci A,
Olivieri D. Airways remodeling is a distinctive feature of
asthma and is related to severity of disease. Chest
1997;111(4):852–7.
22. Leuppi JD, Salome CM, Jenkins CR, et al. Predictive markers
of asthma exacerbations during stepwise dose reduction ofinhaled corticosteroid. Am J Respir Crit Care Med
2001;163(2):406–12.
23. Ponikau JU, Sherris DA, Kephart GM, et al. Features
of airway remodeling and eosinophilic inflammation
in chronic rhinosinusitis: is the histopathology
similar to asthma? J Allergy Clin Immunol 2003;112(5):
877–82.
24. European Network for Understanding Mechanisms of Severe
Asthma. The ENFUMOSA cross-sectional European multi-
centre study of the clinical phenotype of chronic severe
asthma. Eur Respir J 2003; 22(3), 470–7.
25. Meagher LC, Cousin JM, Seckl JR, Haslett C. Opposing
effects of glucocorticoids on the rate of apoptosis in
neutrophilic and eosinophilic granulocytes. J Immunol
1996;156(11):4422–8.
